BC
TPST icon

Broadfin Capital’s Tempest Therapeutics TPST Stock Holding History

Broadfin Capital’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-186
Closed -$442K – 55
2018
Q1 		$442K Sell
186
-2
-1% -$6K 0.07% 50
2017
Q4 		$770K Hold
188
– – 0.13% 42
2017
Q3 		$781K Buy
188
+94
+100% +$402K 0.12% 44
2017
Q2 		$429K Buy
+94
New +$398K 0.05% 52

Other funds holding TPST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Broadfin Capital's TPST Position: Q2 2018 in Review

Broadfin Capital sold out of Tempest Therapeutics (TPST) in Q2 2018, closing a stake of 186 shares — an estimated $442K sold.

Broadfin Capital first reported a position in TPST in Q2 2017 and held it in 4 quarters. The position peaked at $781K in Q3 2017. 33 funds tracked by Wall St. Rank hold TPST as of Q2 2018.

  • Broadfin Capital reported no remaining Tempest Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Broadfin Capital sold 186 Tempest Therapeutics shares in Q2 2018, an estimated $442K.
  • Broadfin Capital first reported a position in Tempest Therapeutics in Q2 2017 and held it in 4 quarters.
  • Broadfin Capital's Tempest Therapeutics position peaked at $781K in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2018.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.